iAssay, Inc.

9921 Carmel Mountain Road, Suite 777
San Diego,  CA  92129

United States
https://www.iAssay.net
  • Booth: 564

iAssay® has developed patented Cloud connected, battery-powered, handheld/small benchtop Point-of-Care Test (POCT) clinical diagnostics devices. Assay agnostic, multi-tech/format POCT cartridges from hundreds of manufacturers are compatible with iAssay® devices. iAssay® SimpleCloud™ Cloud, raw data, time/date stamp, & results are available worldwide via internet portals. Cloud is available to third parties. Interoperability! See a demo of the most unique POCT/Health IT System in the world.

 Press Releases

  • A Novel Approach to Remote Laboratory Testing

    FIND, the Global Alliance for Diagnostics and the iAssay Team Up to Develop Diagnostics

    San Diego — March 23, 2022 — Buruli ulcer is a severely debilitating disease, which starts as an inconspicuous papule and degenerates in large open wounds if left untreated. The causative pathogen is Mycobacterium ulcerans. Treatments exist (antibiotics) but convenient diagnostics do not. Yet, diagnostics are critical to ensure early treatment and proper selection of the antibiotic regimen. The disease is believed to be vastly underreported and reliable epidemiological data are not available, precisely due to the lack of suitable diagnostics. It is estimated that at least 100,000 people are infected in sub-Saharan Africa, probably more. The disease is not life threatening but induces severe disability as large ulcers develop in the limbs and feet.

    A new test for Buruli ulcer is being developed under the leadership of FIND, the global alliance for diagnostics, which has a assembled a consortium of dermatologists (Nagasaki University, Japan), biologists (Swiss Tropical and Public Health Institute, Bern, Switzerland), and assay developers (Drugs & Diagnostics for Tropical Diseases, San Diego, CA), with funding from the Global Health Technology Innovation Fund (GHIT), the Medicor foundation and Anesvad.  

    The test consists of a lateral flow assay that utilizes novel magnetic nanoparticles and antibodies to concentrate and detect the biomarker under scrutiny. The biomarker present in only minute amounts is collected from the wound by means of a swab and applied to the test. Like other lateral flow assays, a test and a control line appear on a nitrocellulose strip. A first-generation prototype is being evaluated in the field in Cameroon (Buruli Ulcer Laboratory Network, Centre Pasteur du Cameroun, Yaoundé) and in Ivory Coast (Hope Commission and Centre Pasteur, Abidjan). To quantify the results and for quality control purposes, the team decided to use a reader to measure the intensity of the test and control lines. The reader had to be adapted to field use and therefore be portable, rugged, and battery operated. Furthermore, data collection in a cloud-based repository was desirable to enable real-time monitoring of the results. Finally, the reader had to be cost-effective.

    iAssay® Inc, a privately held developer of point of care (POC) readers for remote medical diagnostics, is proud to report that the consortium has used iAssay reader model 2030 for its field studies. While a formal reader selection process was not followed, the use of the iAssay reader was based on the urgent identified need to quantify the results of the RDT in the field after the activities had been initiated, as well on the cost, ruggedness, ease to upload data in a cloud-based repository for quick analysis, and previous experience on the use of iAssay by DDTD. Marco Biamonte, CEO of Drugs & Diagnostics for Tropical Diseases says: “The iAssay reader has lived up to expectations and has performed flawlessly. Training users proved to be easy, and it was a pleasure to note that the data was uploaded in the cloud automatically and without issues in a set-and-forget mode”.   Marco adds that even young people have large open wounds showing flesh and bones, and that seeing the frequency and magnitude of these lesions added for him a moral imperative to urgently develop a point of-care rapid test for Buruli ulcer.

     

    iAssay® Inc., announced on January 4th, 2022, that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 17/001,069. The allowed patent includes 19 claims, key claims relating to the processing of multiple unique test devices simultaneously in a common drawer, mechanisms for decoding identifiers, and lateral flow test results based online intensity/color. The patent application is expected to issue in mid-2022

    For more information on  iAssay                                 

    info@iassay.net

    www.iAssay.net

    For more information on DDTD

    Admin@ddtd.org

    www.ddtd.org

  • iAssay, Inc. Joins MetroConnect to Accelerate International Growth

    iAssay, Inc. joins MetroConnect to accelerate international growth

    Export assistance program to support iAssay, Inc. with growth in European and Asian medical diagnostics markets

    San Diego – Today, iAssay, Inc. has been named as one of 15 San Diego companies participating in MetroConnect, World Trade Center San Diego (WTCSD)’s comprehensive export assistance program that helps local companies accelerate their international growth. WTCSD, San Diego City Councilmember Raul Campillo, and nearly 100 community leaders came together to welcome the new cohort today.

    This program will allow iAssay, Inc. to attend international trade shows, expand trade partnerships in current and new foreign markets.

    “We are excited for the opportunity to participate in the MetroConnect program,” said Lonnie Adelman, Founder and CEO of iAssay, Inc. “The in-kind services offered through the program and being able to collaborate with our fellow Cohort VI companies to promote successes all the way around is what makes the program most attractive to iAssay.

    “We applaud iAssay, Inc. for taking the next step in going global,” said Nikia Clarke, executive director of World Trade Center San Diego. “As the San Diego economy continues to recover from the pandemic, we are optimistic about the future. Thanks to JPMorgan Chase and Procopio, the MetroConnect program will continue to build on this momentum and help ensure San Diego’s small and mid-sized businesses have the tools needed to weather future economic downturns, grow quality jobs, and share San Diego-made innovation with the world.”

    Since the program’s debut in 2015, 80 MetroConnect alumni have collectively added 269 new jobs to the region, signed more than 543 new contracts, and set up 22 new overseas facilities. On average, cohort companies grow their exports by an average 63 percent and revenues by 40 percent as part of the program. Alumni include Blue Sky Network, Aira (acquired by Blue Diego Investment Group), Scientist.com, Modern Times, Dr. Bronner’s, Cypher Genomics (acquired by Human Longevity Inc.), Planck Aerosystems, Bitchin’ Sauce, and many more.

    “I’m proud to support and welcome WTCSD’s new cohort and look forward to seeing the companies’ impact on a global scale,” said San Diego City Councilmember Raul Campillo. “Programs like MetroConnect help ensure the world knows just what San Diego is made of—innovative, high-impact products and services across a wide range of industries.”

    iAssay, Inc.joins a cohort of 14 other companies representing a unique cross-section of San Diego’s industries, from genomics to manufacturing to craft brewing – each with plans to take San Diego innovation global.

    Program participants receive a $5,000 grant, a one-year subscription to premium translation software, discounts on international travel, executive workshops on export-related topics and access to a global mentor and service provider network. Participants will also have the opportunity to participate in the program’s final competition – the MetroConnect Grand Prize PitchFest – which will grant an additional $25,000 to help one company further advance its international efforts.

    “Since its launch, the City of San Diego has been a proud supporter of MetroConnect and the nearly 100 businesses it has helped grow internationally,” said San Diego Mayor Todd Gloria. “As Mayor, I’m committed to supporting San Diego’s small businesses on our road to recovery; and international connectivity is an important tool in building economic resilience.”

    The MetroConnect program is highly competitive, with just 15 companies selected based on a variety of criteria, including interest in new markets, interest in targeted metro markets, assessed impact of funds, current international traction and more. Applicants were assessed by a panel of judges, including senior level representatives from Biocom, Connect, CMTC, U.S. Commercial Service, Procopio, and Mitsubishi Electric.

    MetroConnect is co-underwritten by JPMorgan Chase & Co. and Procopio, with additional support provided by American Airlines, British Airways, City of San Diego, Japan Airlines, Mitsubishi Electric, Qualcomm, San Diego and Imperial SBDC Network, SYSTRAN, Takeda Pharmaceuticals, Taylor Guitars, United Kingdom Government Office, YCP Solidiance and more.

    About iAssay, Inc.

    Privately-held iAssay® develops Amazon AWS IT Systems and Cloud connected portable medical devices as a system that enhances the type of Point-of-Care Test (POCT) clinical diagnostics experienced by millions of people and their healthcare providers at pharmacies, doctors’ offices, and at workplaces during the COVID-19 pandemic. Battery-powered, devices are test agnostic, enabling a variety of drug screening and clinical tests by multi-manufacturers to be adapted to a single device. The System drives interoperability! Multi-tech/format POCT cartridges commercialized by hundreds of companies are can be onboarded using iAssay® designed devices and adaptors. iAssay® AWS Cloud validates devices before testing can start, then captures raw data, time/date stamped results available through worldwide internet portals.

    About World Trade Center San Diego

    World Trade Center San Diego (WTCSD) operates as an affiliate of San Diego Regional Economic Development Corporation (EDC). WTCSD works to further San Diego’s global competitiveness by cultivating a pipeline of export-ready firms, attracting, and retaining foreign investment and increasing San Diego’s global profile abroad. sandiegobusiness.org/wtcsd

    ###

 Additional Info

We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth!
Yes
Included in the Export Interest Directory?
Yes
Products to be exported:
Point of Care Diagnostics Devices and Data Management Cloud
Business Needs:
Distributor/Agent/Representative, Investor, Joint Ventures, Licensing Agreements

Categories

Diagnostic IT Solutions
  • Data Analysis & Management/Middleware
    • Diagnostic Testing
  • Cardiac Testing
  • Cholesterol Testing
  • COVID
  • Drug Testing
  • Electrolyte Testing
  • Forensic Testing
  • Infectious Disease Testing
  • Influenza Testing
  • Point of Care Testing
    • Back to the Search
    Loading ...

    :
    :


    Legend
    Available Timeslot
    Scheduled Appointment
    Personal Appointments
    Appointment Request
    Blocked Timeslot
    Restricted Timeslot
    Cancelled
    Declined